Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 461-465

  McLeod, H L ^a,c   Sludden, J ^a,d   Murray, G I ^a   Keenan, R A ^b   Davidson, A I ^b   Park, K ^b   Koruth, M ^b   Cassidy, J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NHS GRAMPIAN   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

5 fluorouracil; Colorectal cancer; Dihydropyrimidine dehydrogenase; Enzyme activity; Pharmacogenetics

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; FLUOROURACIL;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0031973816     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.73     Document Type: Article

References (24)

1. Beck A, Etienne M-C, Cheradame S, Fischel JL, Formento P, Renee N and Milano G (1994) A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522
2. Bradford MM (1976) A rapid method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem 72: 248-254
3. Cao SS, Rustum YM and Spector T (1994) 5-Ethynyluracil (776C85) - modulation of 5-fluorouracil efficacy and therapeutic index in rats hearing advanced colorectal carcinoma. Cancer Res 54: 1507-1510
4. Chazal M, Etienne M-C, Renee N, Bourgeon A, Richelme H and Milano G (1996) Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2: 507-510
5. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G (1995) Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670
6. Fleming RA, Milano G, Thyss A, Etienne M-C, Renee N, Schneider M and Demard F (1992) Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899-2902
7. Hammond AH and Fry JR (1990) The in vivo induction of rat hepatic cytochrome P450-dependent enzyme activities and their maintenance in culture. Biochem Pharmacol 40: 637-642
8. Harris BE, Song R, Soong S and Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201
9. Harris BE, Carpenter JT and Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68: 499-501
10. Heggie GD, Sommadosi J-P, Cross DS, Huster WJ and Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206
11. Ho DH, Townsend L, Luna MA and Bodey GP (1984) Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6: 781-784
12. Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leiehman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412
13. 19F nuclear magnetic resonance spectroscopy. Cancer Res 54: 4321-4326
14. Lu Z-H, Zhang R and Diasio RB (1995) Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 58: 512-522
15. McKay JA, Murray GI, Weaver RJ, Ewen SWB, Melvin WT and Burke MD (1993) Xenobiotic metabolising enzyme expression in colonie neoplasia. Gut 34: 1234-1239
16. McMurrough J and McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41: 425-427
17. Murray GI, Taylor MC, McFadyen MCE, McKay JA, Greenlee WF, Burke MD and Melvin WT (1997) Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57: 3026-3031
18. Naguib FNM, el Kouni MH and Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissue. Cancer Res 45: 5405-5412
19. Naguib FNM, Hao SN and el Kouni MH (1994) Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res 54: 5166-5170
20. Smitkamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BFAM and Peters GJ (1995) DT-diaphorase activity in normal and neoplastic human tissues: an indicator for sensitivity to bioreductive agents? Br J Cancer 72: 917-921
21. Stephan F, Etienne M-C, Wallays C, Milano G and Clergue F (1995) Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 99: 685-688
22. Vreken P, van Kuilenburg ABP, Meinsma R, Smit GPA, Bakker HD, de Abreu RA and van Gennip AH (1996) A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inher Metab Dis 19: 645-654
23. Wang F-S, Aschele C, Sobrero A, Chang Y-M and Bertino JR (1993) Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 53: 3677-3680
24. Wei X, McLeod HL, McMurrough J, Gonzalez FJ and Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98: 610-615